Table 1 Patient characteristics
Intervention group (n = 132) | Non-intervention group (n = 264) | P-values | |
|---|---|---|---|
Observation period (day), Mean ± SD | 1638 ± 81 | 1702 ± 50 | < 0.001 |
Intervention period (day)a, Median (range) | 224 (27–1742) | - | - |
Number of interventions, Median (range) | 5.5 (2–31) | - | - |
Age (year), Mean ± SD | 73.2 ± 12.2 | 72.6 ± 11.8 | 0.62 |
Male | 94 (71.2%) | 188 (71.2%) | 1.00 |
History of stroke (yes) | 20 (15.1%) | 37 (14.0%) | 0.76 |
History of PCI (yes) | 43 (32.5%) | 102 (38.6%) | 0.27 |
History of CABG (yes) | 8 (6.0%) | 25 (9.6%) | 0.34 |
Laboratory data | |||
SCr (mg/dL), Mean ± SD | 1.09 ± 0.48 | 1.06 ± 0.54 | 0.66 |
eGFR (mL/min/1.73m2), Mean ± SD | 55.7 ± 19.4 | 57.2 ± 18.4 | 0.48 |
AST (U/L), Mean ± SD | 29.4 ± 18.6 | 25.6 ± 11.5 | 0.011 |
ALT(U/L), Mean ± SD | 25.7 ± 24.7 | 23.2 ± 16.3 | 0.23 |
Indication for anticoagulation | |||
Atrial fibrillation | 65 (49.2%) | 108 (40.9%) | 0.13 |
Ischemic heart disease | 53 (40.1%) | 116 (43.9%) | 0.52 |
Deep vein thrombosis | 7 (5.3%) | 33 (12.5%) | 0.033 |
Antithrombotic drug | |||
Warfarin | 51 (38.6%) | 103 (39.0%) | 1.00 |
DOAC | 34 (25.7%) | 53 (20.0%) | 0.20 |
Apixaban | 22 (16.7%) | 23 (8.7%) | 0.028 |
Rivaroxaban | 6 (4.5%) | 16 (6.1%) | 0.65 |
Dabigatran | 1 (0.8%) | 14 (5.3%) | 0.025 |
Edoxaban | 5 (3.8%) | 0 | 0.004 |
Antiplatelet drug | 63 (47%) | 141 (53.4%) | 0.29 |
Aspirin | 55 (41.7%) | 132 (50.0%) | 0.14 |
Clopidogrel | 11 (8.3%) | 29 (11.0%) | 0.48 |
Prasugrel | 13 (9.8%) | 16 (6.1%) | 0.22 |
Cilostazole | 3 (2.3%) | 4 (1.5%) | 0.69 |
Ticlopidine | 1 (0.8%) | 3 (1.1%) | 1.00 |
Sarpogrelate | 0 | 3 (1.1%) | 0.55 |